Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4122712 | 0.78 | PKM (0.73) | MAPTNPC1RAB9ASMN1; SMN2KAT2B | |
| SCHEMBL4938057 | 0.78 | CYP2C9 (0.49) | LMNAGAA | |
| SCHEMBL4935806 | 0.75 | KAT2B (0.49) | MAPTNPC1RAB9ASMN1; SMN2KAT2B | |
| SCHEMBL6198859 | 0.74 | KAT2B (0.80) | MAPTNPC1RAB9ASMN1; SMN2KAT2B | |
| SCHEMBL20797666 | 0.74 | KAT2B (0.48) | MAPTNPC1RAB9ASMN1; SMN2KAT2B | |
| SCHEMBL103245 | 0.72 | KMT2A (0.63) | MAPTNPC1RAB9ASMN1; SMN2KAT2B | |
| SCHEMBL4077151 | 0.72 | KAT2B (0.66) | MAPTNPC1RAB9ASMN1; SMN2KAT2B | |
| SCHEMBL7170020 | 0.71 | KAT2B (0.81) | MAPTNPC1RAB9ASMN1; SMN2KAT2B | |
| SCHEMBL6200169 | 0.71 | KAT2B (0.81) | MAPTNPC1RAB9ASMN1; SMN2KAT2B | |
| SCHEMBL12515298 | 0.70 | KAT2B (0.69) | MAPTNPC1RAB9ASMN1; SMN2KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096861-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096861-A1 | Chemical Compounds | CCR5, CXCR4, CXCR3 | MAPT 3251/4885NPC1 243/4885RAB9A 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.